Cover Image
Market Research Report

Chronic Kidney Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

Published by GervanoRA Data Services LLP Product code 769584
Published Content info 175 Pages
Delivery time: 1-2 business days
Price
Back to Top
Chronic Kidney Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018
Published: January 17, 2019 Content info: 175 Pages
Description

GervanoRA's pipeline analysis and opportunity assessment report "Chronic Kidney Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018" analyzed and assessed Chronic Kidney Disease pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Chronic Kidney Disease industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast 2019 - 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

Table of Contents
Product Code: GERPH011

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT MAJOR FINDINGS
  • 2.2. KEY EVENTS IN CHRONIC KIDNEY DISEASE COMPETITIVE SPACE

3. DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION & SYMPTOMS
    • 3.1.1. CLINICAL MANIFESTATIONS
    • 3.1.2. PATHOGENESIS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY AND DISEASE BURDEN
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS

  • 4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
  • 4.2. PRICING AND REIMBURSEMENT
  • 4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
  • 4.4. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

5. PIPELINE ANALYSIS

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE-REGISTRATION MOLECULES
    • 5.1.2. PHASE 3 MOLECULES
    • 5.1.3. PHASE 2 MOLECULES
    • 5.1.4. PHASE 1 MOLECULES
    • 5.1.5. PRECLINICAL MOLECULES
    • 5.1.6. EARLY R&D MOLECULES
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES

6. ESTIMATED APPROVAL TIMELINE

    • 6.1.1. METHODOLOGY
    • 6.1.2. ESTIMATED APPROVAL TIMELINES US & EX-US

7. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 7.1. COMPANIES
    • 7.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
      • 7.1.1.1. ASTRAZENECA PLC
      • 7.1.1.2. ELI LILLY AND COMPANY
      • 7.1.1.3. OPKO HEALTH INC
      • 7.1.1.4. GILEAD SCIENCES, INC
      • 7.1.1.5. ASTELLAS PHARMA
  • 7.2. EMERGING COMPANIES
    • 7.2.1. ALGOMEDIX TRP THERAPEUTICS
    • 7.2.2. ALLENA PHARMACEUTICALS
    • 7.2.3. NOVADIOL INC
    • 7.2.4. PALLADIO BIOSCIENCES
    • 7.2.5. PROLONG PHARMACEUTICALS LLC
    • 7.2.6. PROTEON THERAPEUTICS, INC
    • 7.2.7. REGENMEDTX LLC
    • 7.2.8. RESVERLOGIX
    • 7.2.9. SPHAERA PHARMA
    • 7.2.10. THRASOS THERAPEUTICS
    • 7.2.11. TRICIDA INC
    • 7.2.12. VIDASYM
    • 7.2.13. ANGION BIOMEDICA CORP
    • 7.2.14. KIDNEYCURE LTD
    • 7.2.15. PROMETIC LIFE SCIENCES INC
    • 7.2.16. CORVIDIA THERAPEUTICS
    • 7.2.17. EMBER THERAPEUTICS
    • 7.2.18. INOSITEC AG
    • 7.2.19. KBP BIOSCIENCES CO LTD
    • 7.2.20. MISSION THERAPEUTICS

8. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: CLASSIFICATION OF CKD USING GFR AND ACR CATEGORIES
  • TABLE 03: RECOMMENDATIONS PROVIDED BY AMERICAN COLLEGE OF PHYSICIANS
  • TABLE 04: CKD EPIDEMIOLOGY (2017), FORECAST (2018-2023) IN MILLIONS
  • TABLE 05: CKD FINANCING ACTIVITY IN $M
  • TABLE 06: MAJOR COLLABORATIVE AGREEMENTS IN CKD THERAPEUTIC AREA
  • TABLE 07: MAJOR LICENSING AGREEMENTS IN CKD THERAPEUTIC AREA
  • TABLE 08: MAJOR MERGERS AND PARTNERSHIPS IN CKD THERAPEUTIC AREA
  • TABLE 09: PHASE 3 MOLECULES IN THE CKD DRUG PIPELINE
  • TABLE 10: PHASE 2 MOLECULES IN THE CKD DRUG PIPELINE
  • TABLE 11: PHASE 1 MOLECULES IN THE CKD DRUG PIPELINE
  • TABLE 12: PRECLINICAL MOLECULES IN THE CKD DRUG PIPELINE
  • TABLE 13: CKD DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
  • TABLE 14: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
  • TABLE 15: ASTRAZENECA PRODUCT PORTFOLIO
  • TABLE 16: DRUGS APPROVALS BY ASTRAZENECA
  • TABLE 17: R&D ACTIVITIES OF ASTRAZENECA
  • TABLE 18: CONFERENCES/EVENTS ATTENDED BY ASTRAZENECA
  • TABLE 19: RECENT DEVELOPMENTS MADE BY ASTRAZENECA
  • TABLE 20: ELI LILLY & COMPANY PRODUCT PORTFOLIO
  • TABLE 21: OTHER PHASE 2 AND PHASE 1 PROGRAM
  • TABLE 22: OTHER PHASE 2 AND PHASE 1 PROGRAM
  • TABLE 23: OTHER PHASE 2 AND PHASE 1 PROGRAM
  • TABLE 24: OTHER PHASE 2 AND PHASE 1 PROGRAM
  • TABLE 25: R&D ACTIVITIES OF ELI LILLY & COMPANY
  • TABLE 26: CONFERENCES/EVENTS ATTENDED BY ELI LILLY & COMPANY
  • TABLE 27: RECENT DEVELOPMENTS MADE BY ELI LILLY & COMPANY
  • TABLE 28: R&D ACTIVITIES OF OPKO HEALTH
  • TABLE 29: CONFERENCES/EVENTS ATTENDED BY OPKO HEALTH
  • TABLE 30: RECENT DEVELOPMENTS MADE BY OPKO HEALTH
  • TABLE 31: GILEAD SCIENCES PRODUCT PORTFOLIO
  • TABLE 32: R&D ACTIVITIES OF GILEAD SCIENCES
  • TABLE 33: REGULATORY PROGRESS BY GILEAD SCIENCES
  • TABLE 34: CONFERENCES/EVENTS ATTENDED BY GILEAD SCIENCES
  • TABLE 35: RECENT DEVELOPMENTS MADE BY GILEAD SCIENCES
  • TABLE 36: ASTELLAS PHARMA PRODUCT PORTFOLIO
  • TABLE 37: APPROVALS AND LANCHES BY ASTELLAS PHARMA
  • TABLE 38: R&D ACTIVITIES OF ASTELLAS PHARMA
  • TABLE 39: RECENT DEVELOPMENTS MADE BY ASTELLAS PHARMA
  • TABLE 40: EMERGING OPPORTUNITIES IN CKD THERAPEUTIC AREA
  • TABLE 41: EVENTS/CONFERENCES ATTENDED BY ALGOMEDIX
  • TABLE 42: FUTURE MILESTONE EVENTS OF ALLENA PHARMACEUTICALS
  • TABLE 43: R&D ACTIVITIES BY ALLENA PHARMACEUTICALS
  • TABLE 44: EVENTS/CONFERENCES ATTENDED BY ALLENA PHARMACEUTICALS
  • TABLE 45: R&D ACTIVITIES BY PALLADIO BIOSCIENCES
  • TABLE 46: RECENT DEVELOPMENTS BY PALLADIO BIOSCIENCES
  • TABLE 47: R&D ACTIVITIES BY PROLONG PHARMACEUTICALS
  • TABLE 48: EVENTS/CONFERENCES ATTENDED BY PROLONG PHARMACEUTICALS
  • TABLE 49: EVENTS AND CONFERENCES ATTENDED BY PROTEON THERAPEUTICS
  • TABLE 50: RECENT DEVELOPMENTS BY PROTEON THERAPEUTICS
  • TABLE 51: FUTURE MILESTONE EVENTS OF RESVERLOGIX
  • TABLE 52: R&D ACTIVITIES BY RESVERLOGIX
  • TABLE 53: EVENTS/CONFERENCES ATTENDED BY RESVERLOGIX
  • TABLE 54: RECENT DEVELOPMENTS BY RESVERLOGIX
  • TABLE 55: RECENT DEVELOPMENTS BY SPHAERA PHARMA
  • TABLE 56: FUTURE MILESTONE EVENTS OF TRICIDA INC
  • TABLE 57: R&D ACTIVITIES BY TRICIDA
  • TABLE 58: EVENTS/CONFERENCES ATTENDED BY TRICIDA
  • TABLE 59: R&D ACTIVITIES BY ANGION BIOMEDICA CORP
  • TABLE 60: EVENTS/CONFERENCES ATTENDED BY ANGION BIOMEDICA CORP
  • TABLE 61: RECENT DEVELOPMENTS BY ANGION BIOMEDICA CORP
  • TABLE 62: FUTURE MILESTONE EVENTS OF PROMETIC LIFE SCIENCES
  • TABLE 63: R&D ACTIVITIES BY PROMETIC LIFE SCIENCES
  • TABLE 64: EVENTS/CONFERENCES ATTENDED BY PROMETIC LIFE SCIENCES
  • TABLE 65: RECENT DEVELOPMENTS BY PROMETIC LIFE SCIENCES
  • TABLE 66: RECENT DEVELOPMENTS BY CORVIDIA THERAPEUTICS
  • TABLE 67: AGREEMENTS AND ACQUISITIONS MADE BY EMBER THERAPEUTICS
  • TABLE 68: RECENT DEVELOPMENTS BY INOSITEC
  • TABLE 69: R&D ACTIVITIES BY KBP BIOSCIENCES
  • TABLE 70: EVENTS/CONFERENCES ATTENDED BY KBP BIOSCIENCES
  • TABLE 71: RECENT DEVELOPMENTS BY MISSION THERAPEUTICS
  • TABLE 72: EVENTS/CONFERENCES ATTENDED BY MISSION THERAPEUTICS

LIST OF FIGURES

  • FIGURE 01: KEY PIPELINE EVENTS, 2018-2029
  • FIGURE 02: CKD EPIDEMIOLOGY (2017), FORECAST (2018-2023) IN MILLIONS
  • FIGURE 03: OVERALL DEALS ACTIVITY IN CKD THERAPEUTIC AREA
  • FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
  • FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
  • FIGURE 06: CKD DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 07: CKD DRUG PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 08: CKD DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
  • FIGURE 09: CKD DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINSTRATION
  • FIGURE 10: FINANCIAL INFORMATION OF ASTRAZENECA
  • FIGURE 11: SWOT ANALYSIS OF ASTRAZENECA
  • FIGURE 12: FINANCIAL INFORMATION OF ELI LILLY & COMPANY
  • FIGURE 13: SWOT ANALYSIS OF ELI LILLY & COMPANY
  • FIGURE 14: FINANCIAL INFORMATION OF OPKO HEALTH INC (REVENUES IN $ THOUSANDS AND R&D IN $M)
  • FIGURE 15: SWOT ANALYSIS OF OPKO HEALTH
  • FIGURE 16: FINANCIAL INFORMATION OF GILEAD SCIENCES
  • FIGURE 17: SWOT ANALYSIS OF GILEAD SCIENCES
  • FIGURE 18: FINANCIAL INFORMATION OF ASTELLAS PHARMA
  • FIGURE 19: SWOT ANALYSIS OF ASTELLAS PHARMA
Back to Top